The objectives of the DoCTIS project will be reached through the collaboration of 10 partners coming from public, non-profit and private biomedical research entities.
Multidisciplinary center created in 1994 to support the research carried out in the University Hospital Vall d’Hebron (HUVH), the leading hospital complex in Catalonia and one of the largest in Spain. VHIR covers different steps of the research development, from basic to clinical trials and focuses especially on the development of improved diagnostics, therapies and prevention tools for the prevention of current health issues.
Linköping University (LiU) is one of the larger academic institutions in Sweden, Northern Europe. LiU is innovative, highly ranked and known for close collaboration with business and society. With 27,000 students, 1,200 research students and 4,000 employees, Linköping University, LiU, is Sweden’s fifth largest university and stands at position 28 among the world’s 50 best young universities.
The Centro Nacional de Análisis Genómico (CNAG-CRG) is one of the top European centers in terms of sequencing capacity. Its mission is to carry out projects in DNA sequencing and analysis in collaboration with researchers from Catalonia, Spain and from the international research community in order to ensure the competiveness of our country in the strategic area of genomics.
The mission of the Cardiff University (CU) School of Medicine is to pursue the highest standards of research, education and training, in medicine and related subjects, so as to enhance the health and wealth of the people of Wales and the wider world. It is one of the largest in the UK, employing nearly 500 academic and 300 support staff with over 1,000 undergraduate and 1,100 postgraduate students currently enrolled on medical and science courses.
The Consorci Institut D’Investigacions Biomediques August Pi i Sunyer (IDIBAPS) is a public research centre dedicated to translational research in the field of biomedicine. Its mission is to integrate state of the art basic research and quality clinical research. Founded in 1996, IDIBAPS is formed by the Government of Catalonia, the University of Barcelona’s Faculty of Medicine (UB), the Hospital Clínic de Barcelona (HCB) and the Institut d’Investigacions Biomèdiques de Barcelona of the Spanish Council for Scientific Research (IIBB-CSIC).
The university of Verona was founded in the Fifties and in 1982 it was established as autonomous State University. The University of Verona is dedicated to innovation and to maintaining the high quality of its teaching and research. It now counts more than 22,000 students in life sciences, computer science, socio-economic sciences and humanities and 1,500 teaching and non-teaching staff, dedicated to a continual process of growth and to the development of human, structural and financial resources.
The Charité – Universitätsmedizin Berlin (Charité), CHARITE_DE in this proposal, includes three hospital sites providing medical expertise to the benefit of patients for the entire Berlin – Brandenburg area. The Charité is one of the leading life science institutions in Europe, closely interwining research, clinical development and application.
HudsonAlpha is a nonprofit institute in Huntsville AL, USA committed to improving human health and quality of life through its unique four-fold mission: sparking scientific discoveries that can improve human health and well-being; bringing genomic medicine into clinical care; fostering life sciences entrepreneurship and business growth; and encouraging the creation of a genomics-literate workforce and society.
IMIDomics is a patient-centric drug discovery company dedicated to the advancement of new medicines for Immune-mediated inflammatory diseases (IMIDs). Our goal is to discover new and impactful IMID drugs by focusing on carefully selected patients, and stratifying populations to identify those most likely to respond. IMIDomics is powered by a unique Clinical Discovery Engine™, which integrates and analyzes proprietary clinical, epidemiological and patient-derived biomolecular datasets, generated in partnership with the Vall d’Hebron Institute of Research, to establish a deeper understanding of IMID diseases. IMIDomics has identified previously unrecognized targets, six of which have been selected for development within IMIDomics’ active drug pipeline. By relying on access to well-defined patients and their clinically relevant samples, IMIDomics enhances the probability of successful IMID drug discovery and development for those in need.
Zabala is an independent international consultancy founded in 1986 specialized in comprehensive consultancy services of R&D Innovation management and technology transfer projects. 100% of the ZABALA activity is focused on becoming the innovation a key issue in the organization competitiveness, with a wide range of services to companies, research entities and administrations. It currently provides, on a contract basis, consultancy services to a portfolio of 1.500 organisations